Furthermore, the univariate analysis revealed that advanced NSCLC patients with high mutation signature, ever smoking, first-line ICI treatment, higher PD-L1 expression (≥ 1% percentage) or a high TMB score (≥ 10), could benefit from immunotherapy. Here, CD274 is linked to non-small cell lung carcinoma.